On May 17, 2025, Tectonic Therapeutic, Inc. (NASDAQ: TECX) shared the comprehensive findings from Part A of the Phase 1b clinical study of TX45, a long-acting relaxin therapy, for patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"). These outcomes, which encompass data from 19 patients in Phase 1b, are being disclosed at the European Society of Cardiology (ESC) Heart Failure 2025 Congress in Belgrade, Serbia. Earlier, interim results for 16 patients had been issued in a press release on January 30, 2025.